Advisor Group’s NovoCure NVCR Stock Holding History

Advisor Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2.13M	Sell	25,314 -9,542	-27%	-$770K	0.01%	778
2019 Q3	$2.61M	Buy	34,856 +6,735	+24%	+$539K	0.02%	650
2019 Q2	$1.78M	Buy	28,121 +26,154	+1,330%	+$1.33M	0.01%	808
2019 Q1	$95K	Sell	1,967 -14	-0.7%	-$674	﹤0.01%	2910
2018 Q4	$67K	Sell	1,981 -15,032	-88%	-$550K	﹤0.01%	2982
2018 Q3	$892K	Buy	17,013 +15,775	+1,274%	+$628K	0.01%	1066
2018 Q2	$39K	Buy	+1,238	New	+$34.4K	﹤0.01%	3289
2018 Q1	–	Sell	-389	Closed	-$8K	–	5026
2017 Q4	$8K	Hold	389	–	–	﹤0.01%	4215
2017 Q3	$8K	Sell	389 -2,375	-86%	-$46.7K	﹤0.01%	4088
2017 Q2	$48K	Buy	2,764 +2,375	+611%	+$30.7K	﹤0.01%	2879
2017 Q1	$3K	Hold	389	–	–	﹤0.01%	4299
2016 Q4	$3K	Hold	389	–	–	﹤0.01%	4125
2016 Q3	$3K	Hold	389	–	–	﹤0.01%	4078
2016 Q2	$4K	Buy	+389	New	+$4.87K	﹤0.01%	3883

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Advisor Group's NVCR Position: Q4 2019 in Review

Advisor Group reduced its NovoCure (NVCR) stake by 27% in Q4 2019, selling an estimated $770K and leaving 25,314 shares worth $2.13M. The position accounts for 0.01% of the portfolio, ranked #778.

Advisor Group first reported a position in NVCR in Q2 2016 and has held it in 14 quarters since. The position peaked at $2.61M in Q3 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Advisor Group held 25,314 shares of NovoCure worth $2.13M as of Q4 2019.
Advisor Group sold 9,542 NovoCure shares in Q4 2019, an estimated $770K.
NovoCure made up 0.01% of Advisor Group's portfolio in Q4 2019, its #778 holding.
Advisor Group first reported a position in NovoCure in Q2 2016 and has held it in 14 quarters since.
Advisor Group's NovoCure position peaked at $2.61M in Q3 2019.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.